Abstract
Rosacea is a chronic, inflammatory skin disease that affects more than 15 million people in the United States. It is associated with significant psychosocial, physical, and economic burden. The pathogenesis of rosacea is poorly understood. Initial events include dysregulation in cutaneous neurovascular control and neuroimmune communication. Exacerbating factors may include UV light and infectious agents. Recent therapeutic advances have increased treatment options. Such therapies include avoidance of potential triggers, topical therapies, and systemic therapies. Treatment is targeted at reducing facial erythema and eliminating inciting agents that may contribute to the disease process. The tetracycline class of antibiotics has been most extensively studied for systemic therapy. Novel agents such as α-2 agonists have increased therapeutic options in rosacea.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
